RxDoctor Payments Data

Rufino Talatala, MD

Internal Medicine · Carrollton, TXNPI 1093824153

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 83 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$305
  • GSK$206
  • Novo Nordisk$130
  • Boehringer Ingelheim$96
  • Amarin Pharma, Inc.$88
  • Merck$61
  • plus $225 from 11 others

What the payments were for

  • Food & beverage$1,08097%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,110 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,249
Medicare patients
205
Services billed
953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$182,987
OzempicSemaglutide46$97,127
FarxigaDapagliflozin Propanediol54$57,974
JanuviaSitagliptin Phosphate54$52,100
EliquisApixaban34$38,159
Breo ElliptaFluticasone/Vilanterol68$36,975
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$26,870
RybelsusSemaglutide14$21,280
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$20,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,680
SymbicortBudesonide/Formoterol Fumarate42$14,795
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$14,451
Janumet XrSitagliptin Phos/Metformin Hcl14$12,999
LinzessLinaclotide12$11,693
Humalog Kwikpen U-100Insulin Lispro31$11,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$96$182,987131 claims
Novo NordiskOzempic, Rybelsus$130$118,40760 claims
AstraZenecaFarxiga, Symbicort$305$72,76996 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$206$65,442108 claims
MerckJanuvia, Janumet Xr$61$65,09968 claims
PfizerEliquis$54$38,15934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →